2-((Tert-butyldimethylsilyl)oxy)acetaldehyde → HCID 67347933, compound

HRID 1401767Notes

Reaction equation

HRID 1401767 reaction equation
Cl.[CH3:2][C:3]1([CH3:24])[C:11]2[C:6](=[CH:7][C:8]([C:12]3[N:13]=[C:14]([N:17]4[CH2:22][CH2:21][CH:20]([NH2:23])[CH2:19][CH2:18]4)[S:15][CH:16]=3)=[CH:9][CH:10]=2)[CH2:5][CH2:4]1.[Si]([O:32][CH2:33][CH:34]=O)(C(C)(C)C)(C)C.C[N+](C)(C)C.C1COCC1>>[CH3:2][C:3]1([CH3:24])[C:11]2[C:6](=[CH:7][C:8]([C:12]3[N:13]=[C:14]([N:17]4[CH2:22][CH2:21][CH:20]([NH:23][CH2:34][CH2:33][OH:32])[CH2:19][CH2:18]4)[S:15][CH:16]=3)=[CH:9][CH:10]=2)[CH2:5][CH2:4]1

Participants

4

Reactant 3

HCID 41877882-((Tert-butyldimethylsilyl)oxy)acetaldehydeHCID 67323525HCID 67323525, compoundHCID 86671824HCID 86671824, compound

Product 1

HCID 67347933HCID 67347933, compound

Procedure

The preparation is carried out starting from 1-[4-(1,1-dimethylindan-5-yl)thiazol-2-yl]piperidin-4-ylamine hydrochloride and (tert-butyldimethylsilanyloxy)acetaldehyde. The protecting group is cleaved off as already described by means of a 1M tetramethylammonium/THF solution. The product was purified by means of preparative HPLC and converted into the hydrochloride.

Workup

  1. customThe product was purified by means of preparative HPLC

Sources & evidence

ORD record
ord-2b13bee4f2174476ae1826021f33a43f
Source dataset
uspto-grants-2014_12
Patent number
US08907098B2

Reaction notes

Loading…